Why the study?
Although If is upregulated in failing and infarcted hearts, its implication in disease mechanisms remained unresolved.
Does pharmacological inhibition of If prevent ventricular remodeling in a transgenic mouse model of HCN4 overexpression?
Does pharmacological inhibition of If prevent ventricular remodeling in a transgenic mouse model of HCN4 overexpression?
Answers are grounded in this paper and cite their sources.
Augmented myocardial If alters intracellular Ca2+ homeostasis leading to structural cardiac changes, and its pharmacological inhibition may serve as a therapeutic mechanism to prevent cardiomyopathy.
HCN channels underlie the depolarizing funny current (I f ) that contributes importantly to cardiac pacemaking. I f is upregulated in failing and infarcted hearts, but its implication in disease mechanisms remained unresolved. We generated transgenic mice ( HCN4 tg/wt ) to assess functional consequences of HCN4 overexpression-mediated I f increase in cardiomyocytes to levels observed in human heart failure. HCN4 tg/wt animals exhibit a dilated cardiomyopathy phenotype with increased cellular arrhythmogenicity but unchanged heart rate and conduction parameters. I f augmentation induces a diastolic Na + influx shifting the Na + /Ca 2+ exchanger equilibrium towards ‘reverse mode’ leading to increased [Ca 2+ ] i . Changed Ca 2+ homeostasis results in significantly higher systolic [Ca 2+ ] i transients and stimulates apoptosis. Pharmacological inhibition of I f prevents the rise of [Ca 2+ ] i and protects from ventricular remodeling. Here we report that augmented myocardial I f alters intracellular Ca 2+ homeostasis leading to structural cardiac changes and increased arrhythmogenicity. Inhibition of myocardial I f per se may constitute a therapeutic mechanism to prevent cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Yampolsky et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: